@article{f519fbf22e3e4749bbe7a716bae8c5ba,
title = "Assessment and treatment of patients with type 2 myocardial infarction and acute nonischemic myocardial injury",
abstract = "Although coronary thrombus overlying a disrupted atherosclerotic plaque has long been considered the hallmark and the primary therapeutic target for acute myocardial infarction (MI), multiple other mechanisms are now known to cause or contribute to MI. It is further recognized that an MI is just one of many types of acute myocardial injury. The Fourth Universal Definition of Myocardial Infarction provides a taxonomy for acute myocardial injury, including 5 subtypes of MI and nonischemic myocardial injury. The diagnosis of MI is reserved for patients with myocardial ischemia as the cause of myocardial injury, whether attributable to acute atherothrombosis (type 1 MI) or supply/demand mismatch without acute atherothrombosis (type 2 MI). Myocardial injury in the absence of ischemia is categorized as acute or chronic nonischemic myocardial injury. However, optimal evaluation and treatment strategies for these etiologically distinct diagnoses have yet to be defined. Herein, we review the epidemiology, risk factor associations, and diagnostic tools that may assist in differentiating between nonischemic myocardial injury, type 1 MI, and type 2 MI. We identify limitations, review new research, and propose a framework for the diagnostic and therapeutic approach for patients who have suspected MI or other causes of myocardial injury.",
keywords = "Heart injuries, Myocardial infarction, Myocardial ischemia",
author = "DeFilippis, {Andrew P.} and Chapman, {Andrew R.} and Mills, {Nicholas L.} and {De Lemos}, {James A.} and Armin Arbab-Zadeh and Newby, {L. Kristin} and Morrow, {David A.}",
note = "Funding Information: Dr DeFilippis has grant support from the National Institutes of Health, Astra-Zeneca, and has received consulting income from Radiometer. Dr Chapman has had research support and speaker fees from Abbott Diagnostics and Siemens Healthineers. Dr Mills has received consulting income from Abbott Diagnostics, Siemens Healthineers, Roche Diagnostics, and Singulex, and the University of Edinburgh has received research grants from Abbott Diagnostics and Siemens Healthineers. Drs Chapman and Mills are supported by the British Heart Foundation through personal fellowships (FS/16/75/32533, FS/16/14/32023) and a Research Excellence Award (RE/18/5/34216). Dr de Lemos has received grant support from Roche Diagnostics and Abbott Diagnostics, and consulting income from Roche Diagnostics, Abbott Diagnostics, Siemens Health Care Diagnostics, Ortho Clinical Diagnostics, Quidel Cardiovascular, Radiometer, and Jannsen. Dr Newby has received research grant support from Boehringer-Ingelheim, GlaxoSmithKline, and Amylin-BMS, and consulting honoraria from Ortho-Clinical Diagnostics, Roche Diagnostics, Metanomics, and BioKier. Dr Morrow reports research grants from Abbott Laboratories, Amgen, AstraZen-eca, BRAHMS, Eisai, GSK, Medicines Co, Merck, Novartis, Pfizer, Roche, Takeda, and consulting fees from Abbott Laboratories, Aralez, AstraZeneca, Bayer, In-Cardia, and Roche. Dr Arbab-Zadeh reports no conflicts. Publisher Copyright: {\textcopyright} 2019 American Heart Association, Inc.",
year = "2019",
month = nov,
day = "12",
doi = "10.1161/CIRCULATIONAHA.119.040631",
language = "English (US)",
volume = "140",
pages = "1661--1678",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "20",
}